ATE129638T1 - Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit. - Google Patents

Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.

Info

Publication number
ATE129638T1
ATE129638T1 AT91916904T AT91916904T ATE129638T1 AT E129638 T1 ATE129638 T1 AT E129638T1 AT 91916904 T AT91916904 T AT 91916904T AT 91916904 T AT91916904 T AT 91916904T AT E129638 T1 ATE129638 T1 AT E129638T1
Authority
AT
Austria
Prior art keywords
urine
matter
separating
acidified
phenylacetylaminopiperidine
Prior art date
Application number
AT91916904T
Other languages
English (en)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Application granted granted Critical
Publication of ATE129638T1 publication Critical patent/ATE129638T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT91916904T 1990-09-12 1991-08-21 Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit. ATE129638T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/581,022 US5116622A (en) 1990-09-12 1990-09-12 Methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
ATE129638T1 true ATE129638T1 (de) 1995-11-15

Family

ID=24323585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91916904T ATE129638T1 (de) 1990-09-12 1991-08-21 Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.

Country Status (10)

Country Link
US (1) US5116622A (de)
EP (1) EP0500901B1 (de)
AT (1) ATE129638T1 (de)
AU (1) AU642045B2 (de)
DE (1) DE69114261T2 (de)
DK (1) DK0500901T3 (de)
ES (1) ES2078545T3 (de)
GR (1) GR3018437T3 (de)
WO (1) WO1992004043A1 (de)
ZA (1) ZA917016B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
US5391575A (en) * 1994-05-04 1995-02-21 Burzynski; Stanislaw R. Method for treating neurofibromatosis
ATE310505T1 (de) * 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US4705796A (en) * 1986-08-25 1987-11-10 Stereochemical Genetics, Inc. Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
EP0500901A1 (de) 1992-09-02
DE69114261D1 (de) 1995-12-07
GR3018437T3 (en) 1996-03-31
EP0500901B1 (de) 1995-11-02
US5116622A (en) 1992-05-26
DE69114261T2 (de) 1996-04-18
ES2078545T3 (es) 1995-12-16
AU8620591A (en) 1992-03-30
AU642045B2 (en) 1993-10-07
DK0500901T3 (da) 1996-03-04
ZA917016B (en) 1992-06-24
WO1992004043A1 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
US5208041A (en) Essentially pure human parathyroid hormone
JP6419844B2 (ja) Ｃｙｓ連結された抗体−薬物コンジュゲートの精製方法
SE7910483L (sv) Farmaceutisk komposition med tumorhemmande effekt
LV12766A (lv) Composition of l-dopa esters
HK1004340B (en) Essentially pure human parathyroid hormone
US4172071A (en) Chromophore blue adsorbent method for the purification of preparations having an interferon type activity
CA2124329A1 (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
Holtskog et al. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties
US20140004136A1 (en) Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
DE69114261D1 (de) Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.
Ishizaka et al. Unique features of human basophilic granulocytes developed in in vitro culture
Breyer Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats
Noro et al. Murine IgA binding factors (IgA-BF) suppressing IgA production: characterization and target specificity of IgA-BF.
Abdulwajid et al. Nickel-sequestering renal glycoprotein.
CN121574085A (zh) 缀合物及其用途
KR930004471A (ko) 항생 물질 GE 2270 인자 C₂ａ
JP2004503299A (ja) ビオチン誘導体
EP0346810A3 (de) Heparin zur Behandlung von Lupus
EP1067138B1 (de) Hydroxyprolin derivate
Walker et al. The isolation of two peptides from a non-histone chromosomal protein showing irregular charge distribution within the molecule
EP0254647A2 (de) Arzneimittel zur Behandlung von Autoimmunkrankheiten
JPS6254086B2 (de)
Iwata et al. Augmentation of the antibody response by antigen-specific glycosylation-enhancing factor.
Scourides et al. Analytical and preparative reverse phase HPLC of porphyrin C and N, N′-diacetyl porphyrin C
Ziyavitdinov et al. Development of a method for the complex isolation of physiologically active components from bee venom

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee